Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes

Toxicology and Applied Pharmacology

Volumn 262, Issue 3, 2012, Pages 217-222

  Morzadec, Claudie ^a   Macoch, Mélinda ^a   Robineau, Marc ^a   Sparfel, Lydie ^a   Fardel, Olivier ^a,b   Vernhet, Laurent ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Human Th17 lymphocytes; IL 17A; Inflammatory diseases; Inorganic arsenic

Indexed keywords

ARSENIC; CD3 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 17; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; NORMAL HUMAN; PLASMA; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL;

ARSENICALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKINS; LYMPHOCYTE ACTIVATION; REAL-TIME POLYMERASE CHAIN REACTION; TH17 CELLS;

MURINAE; MUS;

EID: 84863818175     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.05.004     Document Type: Article

References (31)

1. Biswas R., Ghosh P., Banerjee N., Das J.K., Sau T., Banerjee A., Roy S., Ganguly S., Chatterjee M., Mukherjee A., Giri A.K. Analysis of T-cell proliferation and cytokine secretion in the individuals exposed to arsenic. Hum. Exp. Toxicol. 2008, 27:381-386.
2. Bobé P., Bonardelle D., Benihoud K., Opolon P., Chelbi-Alix M.K. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 2006, 108:3967-3975.
3. Broady R., Yu J., Chow V., Tantiworawit A., Kang C., Berg K., Martinka M., Ghoreishi M., Dutz J., Levings M.K. Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood 2010, 116:5748-5751.
4. Chen Z., Tato C.M., Muul L., Laurence A., O'Shea J.J. Dintinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007, 56:2936-2946.
5. Chen Y., Parvez F., Gamble M., Islam T., Ahmed A., Argos M., Graziano J.H., Ahsan H. Arsenic exposure at low-to-moderate levels and skin lesions, arsenic metabolism, neurological functions, and biomarkers for respiratory and cardiovascular diseases: review of recent findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. Toxicol. Appl. Pharmacol. 2009, 239:184-192.
6. Chen S.J., Zhou G.B., Zhang X.W., Mao J.H., de Thé H., Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011, 117:6425-6437.
7. Damsker J.M., Hansen A.M., Caspi R.R. Th1 and Th17 cells: adversaries and collaborators. Ann. N. Y. Acad. Sci. 2011, 1183:211-221.
8. Galicia G., Leyva R., Tenorio E.P., Ostrosky-Wegman P., Saavedra R. Sodium arsenite retards proliferation of PHA-activated T cells by delaying the production and secretion of IL-2. Int. Immunopharmacol. 2003, 3:671-682.
9. Hirahara K., Ghoreschi K., Laurence A., Yang X.P., Kanno Y., O'Shea J.J. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 2011, 21:425-434.
10. Hou L.F., He S.J., Li X., Yang Y., He P.L., Zhou Y., Zhu F.H., Yang Y.F., Li Y., Tang W., Zuo J.P. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum. 2011, 63:2445-2455.
11. Iwakura Y., Ishigame H., Saijo S., Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011, 34:149-162.
12. Jeanne M., Lallemand-Breitenbach V., Ferhi O., Koken M., Le Bras M., Duffort S., Peres L., Berthier C., Soilihi H., Raught B., de Thé H. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010, 13:88-98.
13. Kappel L.W., Goldberg G.L., King C.G., Suh D.Y., Smith O.M., Ligh C., Holland A.M., Grubin J., Mark N.M., Liu C., Iwakura Y., Heller G., van den Brink M.R. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009, 113:945-952.
14. Kavian N., Marut W., Servettaz A., Laude H., Nicco C., Chéreau C., Weill B., Batteux F. Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease. J. Immunol. 2012, 10.4049/jimmunol.1103538.
15. Kumagai Y., Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu. Rev. Pharmacol. Toxicol. 2007, 47:243-262.
16. Lemarie A., Morzadec C., Bourdonnay E., Fardel O., Vernhet L. Human macrophages constitute targets for immunotoxic inorganic arsenic. J. Immunol. 2006, 177:3019-3027.
17. Leppkes M., Becker C., Ivanov I.I., Hirth S., Wirtz S., Neufert C., Pouly S., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Becher B., Littman D.R., Neurath M.F. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009, 136:257-267.
18. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 2008, 9:641-649.
19. Martin-Chouly C., Morzadec C., Bonvalet M., Galibert M.D., Fardel O., Vernhet L. Inorganic arsenic alters expression of immune and stress response genes in activated primary human T lymphocytes. Mol. Immunol. 2011, 48:956-965.
20. Mizuguchi M., Asao H., Hara T., Higuchi M., Fujii M., Nakamura M. Transcriptional activation of the interleukin-21 gene and its receptor gene by human T-cell leukemia virus type 1 Tax in human T-cells. J. Biol. Chem. 2009, 284:25501-25511.
21. Monteleone G., Pallone F., Macdonald T.T. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol. Sci. 2009, 30:441-447.
22. Schraml B.U., Hildner K., Ise W., Lee W.L., Smith W.A., Solomon B., Sahota G., Sim J., Mukasa R., Cemerski S., Hatton R.D., Stormo G.D., Weaver C.T., Russell J.H., Murphy T.L., Murphy K.M. The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature 2009, 460:405-409.
23. Shen Z.X., Chen G.Q., Ni J.H., Li X.S., Xiong S.M., Qiu Q.Y., Zhu Z., Tang W., Sun G.L., Yang K.Q., Chen Y., Zhou L., Fang Z.W., Wang Y.T., Ma J., Zhang P., Zhang T.D., Chen S.J., Chen Z., Wang Z.Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
24. Singer M., Trugnan G., Chelbi-Alix M.K. Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-kappaB down-regulation and caspase-3 activation. Innate Immunol. 2011, 17:365-374.
25. Soto-Pena G.A., Luna A.L., Acosta-Saavedra L., Conde P., Lopez-Carrillo L., Cebrian M.E., Bastida M., Calderon-Aranda E.S., Vega L. Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J. 2006, 20:779-781.
26. Unutmaz D. RORC2: the master of human Th17 cell programming. Eur. J. Immunol. 2009, 39:1452-1455.
27. Wang L., Yu C.R., Kim H.P., Liao W., Telford W.G., Egwuagu C.E., Leonard W.J. Key role for IL-21 in experimental autoimmune uveitis. Proc. Natl. Acad. Sci. 2011, 108:9542-9547.
28. Wetzler M., Brady M.T., Tracy E., Li Z.R., Donohue K.A., O'Loughlin K.L., Cheng Y., Mortazavi A., McDonald A.A., Kunapuli P., Wallace P.K., Baer M.R., Cowell J.K., Baumann H. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin. Cancer Res. 2006, 12:6817-6825.
29. Yang L., Anderson D.E., Baecher-Allan C., Hastings W.D., Bettelli E., Oukka M., Kuchroo V.K., Hafler D.A. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352.
30. Zhao X.Y., Xu L.L., Lu S.Y., Huang X.J. IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur. J. Immunol. 2011, 41:514-526.
31. Zhu J., Paul W.E. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol. Rev. 2010, 238:247-262.